Explore the vast range of titles available.

Key Points Several drugs that target the tumour suppressor p53 pathway are now in clinical trials. Small-molecule drugs that inhibit the protein–protein interaction between p53 and the E3 ubiquitin protein ligase MDM2 have been developed by many academic and pharmaceutical groups; some can induce complete regressions in xenograft models of human cancer. Stapled peptides are an alternative to classical small-molecule inhibitors; they are active in animal models of cancer as dual inhibitors of the p53–MDM2 and p53–MDM4 interactions. The potential side effects of activating p53 in normal tissues are still being explored. So far, the major effect seems to be the induction of neutropenia. The activation of p53 by the MDM2 inhibitors can induce growth arrest, senescence or apoptosis in tumour cells. Studies to understand this variation have identified expression levels of key components of both the intrinsic and extrinsic apoptotic machinery as key regulators. Drug combinations that target these apoptotic pathways may increase the efficacy of p53 therapy. Drugs that reactivate the wild-type functions of mutant p53 are also in clinical trials, although their mechanism of action is still unclear. Structural studies of mutant p53 are providing druggable sites on the surface of the protein to which small molecules can bind. As well as inducing apoptotic death in cancer cells, the p53 pathway has a role in preventing the earliest development of cancer. This surveillance function of p53 is distinct and involves a discrete group of p53-induced genes that regulate DNA repair and metabolism, and does not require the genes encoding p53-upregulated modulator of apoptosis ( PUMA ), phorbol-12-myristate-13-acetate-induced protein 1 ( PMAIP1 ; also known as NOXA ) or cyclin-dependent kinase inhibitor 1A ( CDKN1A ). The p53-inducing drugs may have a role in chemoprevention. The tumour suppressor p53 is the most frequently mutated gene in human cancer, and drugs that restore or activate the p53 pathway have now reached clinical trials. Most of these drugs inhibit MDM2, a negative regulator of p53. In this Review, Lane and colleagues provide an overview of the different therapeutic approaches to targeting the p53 pathway and discuss the state of development of p53 pathway modulators. The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more than half of all human tumours carrying mutations in this particular gene. Intense efforts to develop drugs that could activate or restore the p53 pathway have now reached clinical trials. The first clinical results with inhibitors of MDM2, a negative regulator of p53, have shown efficacy but hint at on-target toxicities. Here, we describe the current state of the development of p53 pathway modulators and new pathway targets that have emerged. The challenge of targeting protein–protein interactions and a fragile mutant transcription factor has stimulated many exciting new approaches to drug discovery.

Antimicrobial peptides (AMPs) are promising next generation antibiotics that hold great potential for combating bacterial resistance. AMPs can be both bacteriostatic and bactericidal, induce rapid killing and display a lower propensity to develop resistance than do conventional antibiotics. Despite significant progress in the past 30 years, no peptide antibiotic has reached the clinic yet. Poor understanding of the action mechanisms and lack of rational design principles have been the two major obstacles that have slowed progress. Technological developments are now enabling multidisciplinary approaches including molecular dynamics simulations combined with biophysics and microbiology toward providing valuable insights into the interactions of AMPs with membranes at atomic level. This has led to increasingly robust models of the mechanisms of action of AMPs and has begun to contribute meaningfully toward the discovery of new AMPs. This review discusses the detailed action mechanisms that have been put forward, with detailed atomistic insights into how the AMPs interact with bacterial membranes. The review further discusses how this knowledge is exploited toward developing design principles for novel AMPs. Finally, the current status, associated challenges, and future directions for the development of AMP therapeutics are discussed.

CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are de novo resistant to CDK4/6 inhibitors and others develop acquired resistance. Here, we show that p16 overexpression is associated with reduced antitumor activity of CDK4/6 inhibitors in patient-derived xenografts ( n  = 37) and estrogen receptor-positive breast cancer cell lines, as well as reduced response of early and advanced breast cancer patients to CDK4/6 inhibitors ( n  = 89). We also identified heterozygous RB1 loss as biomarker of acquired resistance and poor clinical outcome. Combination of the CDK4/6 inhibitor ribociclib with the PI3K inhibitor alpelisib showed antitumor activity in estrogen receptor-positive non-basal-like breast cancer patient-derived xenografts, independently of PIK3CA , ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy. Our results offer insights into predicting primary/acquired resistance to CDK4/6 inhibitors and post-progression therapeutic strategies. CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.

The transcription factor p53 regulates cellular integrity in response to stress. p53 is mutated in more than half of cancerous cells, with a majority of the mutations localized to the DNA binding domain (DBD). In order to map the structural and dynamical features of the DBD, we carried out multiple copy molecular dynamics simulations (totaling 0.8 μs). Simulations show the loop 1 to be the most dynamic element among the DNA-contacting loops (loops 1-3). Loop 1 occupies two major conformational states: extended and recessed; the former but not the latter displays correlations in atomic fluctuations with those of loop 2 (~24 Å apart). Since loop 1 binds to the major groove whereas loop 2 binds to the minor groove of DNA, our results begin to provide some insight into the possible mechanism underpinning the cooperative nature of DBD binding to DNA. We propose (1) a novel mechanism underlying the dynamics of loop 1 and the possible tread-milling of p53 on DNA and (2) possible mutations on loop 1 residues to restore the transcriptional activity of an oncogenic mutation at a distant site.

Arrhythmogenic cardiomyopathy (AC) is a common cause of sudden cardiac arrest and death in young adults. It can be induced by different types of mutations throughout the desmoplakin gene including the R2834H mutation in the extreme carboxyterminus tail of desmoplakin (DP CT) which remains structurally uncharacterized and poorly understood. Here, we have created 3D models of DP CT which show the structural effects of AC-inducing mutations as well as the implications of post-translational modifications (PTMs). Our results suggest that, in absence of PTMs, positively charged wildtype DP CT likely folds back onto negatively-charged plectin repeat 14 of nearby plakin repeat domain C (PRD C) contributing to the recruitment of intermediate filaments (IFs). When phosphorylated and methylated, negatively-charged wildtype DP CT would then fold back onto positively-charged plectin repeat 17 of PRD C, promoting the repulsion of intermediate filaments. However, by preventing PTMs, the R2834H mutation would lead to the formation of a cytoplasmic mutant desmoplakin with a constitutively positive DP CT tail that would be aberrantly recruited by cytoplasmic IFs instead of desmosomes, potentially weakening cell-cell contacts and promoting AC. Virtual screening of FDA-approved drug libraries identified several promising drug candidates for the treatment of cardiocutaneous diseases through drug repurposing.

Barnacles employ a protein-based cement to firmly attach to immersed substrates. The cement proteins (CPs) have previously been identified and sequenced. However, the molecular mechanisms of adhesion are not well understood, in particular, because the three-dimensional molecular structure of CPs remained unknown to date. Here, we conducted multi-dimensional nuclear magnetic resonance (NMR) studies and molecular dynamics (MD) simulations of recombinant Megabalanus rosa Cement Protein 20 ( r MrCP20). Our NMR results show that r MrCP20 contains three main folded domain regions intervened by two dynamic loops, resulting in multiple protein conformations that exist in equilibrium. We found that 12 out of 32 Cys in the sequence engage in disulfide bonds that stabilize the β -sheet domains owing to their placement at the extremities of β -strands. Another feature unveiled by NMR is the location of basic residues in turn regions that are exposed to the solvent, playing an important role for intermolecular contact with negatively charged surfaces. MD simulations highlight a highly stable and conserved β -motif ( β 7- β 8), which may function as nuclei for amyloid-like nanofibrils previously observed in the cured adhesive cement. To the best of our knowledge, this is the first report describing the tertiary structure of an extracellular biological adhesive protein at the molecular level. This article is part of the theme issue ‘Transdisciplinary approaches to the study of adhesion and adhesives in biological systems’.

The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more than half of all human tumours carrying mutations in this particular gene. Intense efforts to develop drugs that could activate or restore the p53 pathway have now reached clinical trials. The first clinical results with inhibitors of MDM2, a negative regulator of p53, have shown efficacy but hint at on-target toxicities. Here, we describe the current state of the development of p53 pathway modulators and new pathway targets that have emerged. The challenge of targeting protein-protein interactions and a fragile mutant transcription factor has stimulated many exciting new approaches to drug discovery.

Heterozygous HNF1A gene mutations can cause maturity onset diabetes of the young 3 (MODY3), characterized by insulin secretion defects. However, specific mechanisms of MODY3 in humans remain unclear due to lack of access to diseased human pancreatic cells. Here, we utilize MODY3 patient-derived human induced pluripotent stem cells (hiPSCs) to study the effect(s) of a causal HNF1A +/H126D mutation on pancreatic function. Molecular dynamics simulations predict that the H126D mutation could compromise DNA binding and gene target transcription. Genome-wide RNA-Seq and ChIP-Seq analyses on MODY3 hiPSC-derived endocrine progenitors reveal numerous HNF1A gene targets affected by the mutation. We find decreased glucose transporter GLUT2 expression, which is associated with reduced glucose uptake and ATP production in the MODY3 hiPSC-derived β-like cells. Overall, our findings reveal the importance of HNF1A in regulating GLUT2 and several genes involved in insulin secretion that can account for the insulin secretory defect clinically observed in MODY3 patients. Heterozygous HNF1A mutations can give rise to maturity onset diabetes of the young 3 (MODY3), characterized by insulin secretion defects. Here the authors show that MODY3-related HNF1A mutation in patient hiPSCderived pancreatic cells decreases glucose transporter GLUT2 expression due to compromised DNA binding.

The TP53 gene is mutated in 50% of reported cancer cases and the p53 pathway is often partially inactivated in the remaining 50%. Clinical trials assessing agents that exploit the p53 system are ongoing. This Review discusses the mechanism of action of these treatments and the future of p53-based therapy. Mutations in the TP53 gene are a feature of 50% of all reported cancer cases. In the other 50% of cases, the TP53 gene itself is not mutated but the p53 pathway is often partially inactivated. Cancer therapies that target specific mutant genes are proving to be highly active and trials assessing agents that exploit the p53 system are ongoing. Many trials are aimed at stratifying patients on the basis of TP53 status. In another approach, TP53 is delivered as a gene therapy; this is the only currently approved p53-based treatment. The p53 protein is overexpressed in many cancers and p53-based vaccines are undergoing trials. Processed cell-surface p53 is being exploited as a target for protein–drug conjugates, and small-molecule drugs that inhibit the activity of MDM2, the E3 ligase that regulates p53 levels, have been developed by several companies. The first MDM2 inhibitors are being trialed in both hematologic and solid malignancies. Finally, the first agent found to restore the active function of mutant TP53 has just entered the clinic. Here we discuss the basis of these trials and the future of p53-based therapy. Key Points 151 trials exploiting the p53 pathway have been conducted TP53 gene therapy (Gendicine) using an adenovirus vector was approved by the Chinese State Food and Drug Administration (SFDA) in 2003 Small-molecule inhibitors of the p53–MDM2 interaction are efficacious in animal models and are in clinical trials for the treatment of solid and hematologic malignancies Cyclotherapy—using a p53 activator to protect normal tissue from cytotoxic drugs and increase the therapeutic index in the treatment of TP53 -mutant cancer—was effective in animal studies

Cyclic peptides are promising drug candidates due to their ability to modulate intracellular protein–protein interactions, a property often inaccessible to small molecules. However, their typically poor membrane permeability limits therapeutic applicability. Accurate computational prediction of permeability can accelerate the identification of cell-permeable candidates, reducing reliance on time-consuming and costly experimental screening. Although deep learning has shown potential in predicting molecular properties, its application in permeability prediction remains underexplored. A systematic evaluation of these models is important to assess current capabilities and guide future development. In this study, we conduct a comprehensive benchmark of 13 machine learning models for predicting cyclic peptide membrane permeability. These models cover four types of molecular representations: fingerprints, SMILES strings, molecular graphs, and 2D images. We use experimentally measured PAMPA permeability data from the CycPeptMPDB database, comprising nearly 6000 cyclic peptides, and evaluate performance across three prediction tasks: regression, binary classification, and soft-label classification. Two data-splitting strategies, random split and scaffold split, are used to assess the generalizability of trained models. Our results show that model performance depends strongly on molecular representation and model architecture. Graph-based models, particularly the Directed Message Passing Neural Network (DMPNN), consistently achieve top performance across tasks. Regression generally outperforms classification. Scaffold-based splitting, although intended to more rigorously assess generalization, yields substantially lower model generalizability compared to random splitting. Comparing prediction errors with experimental variability highlights the practical value of current models while also indicating room for further improvement. Scientific contributions This study presents the first comprehensive benchmark of 13 machine learning models for predicting the membrane permeability of cyclic peptides. By evaluating multiple molecular representations and task formulations on a curated experimental dataset, the work reveals key performance trends, highlighting the superiority of graph-based models, the advantages of regression over classification, and the limitations of scaffold-based data splitting. These findings offer actionable insights for future model development and evaluation in cyclic peptide research.